FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to drugs and concerns a combination for tumour cell growth inhibition containing a cytotoxic compound selected from camptothecin compounds; metabolic antagonists; periwinkle alkaloids; taxanes; platinum compounds; topoisomerase 2 inhibitors; and a combination of two or more said types, or a signal transfer inhibitor selected from antibodies a target of which is EGFR receptor; tyrosine kinase EGFR inhibitors; from antibodies a target of which is a VEGF/VEGF receptor system; PDGFR inhibitors; Raf inhibitors and PKB transfer inhibitors in an effective amount and a compound of formula (IV).
, where R1, R2, R11, T, U and g have the values specified in formula.
EFFECT: what is offered is a pharmaceutical composition, a method for tumour cell growth inhibition, a method of treating a malignant growth in a patient and application of the combination for preparing a drug; the new effective combinations for tumour cell growth inhibition are presented.
77 cl, 20 dwg, 7 tbl, 257 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS USED IN PHARMACEUTICS | 2006 |
|
RU2436575C2 |
| 3,4-SUBSTITUTED 1H-PIRAZOLE COMPOUNDS AND THEIR APPLICATION AS CYCLIN-DEPENDANT KINASES (CDK) AND MODULATORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | 2004 |
|
RU2408585C2 |
| PHARMACEUTICAL COMPOUNDS | 2015 |
|
RU2687060C2 |
| 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | 2016 |
|
RU2736123C1 |
| PHARMACEUTICAL COMBINATIONS CONTAINING PYRIDO[4,3-d]PYRIMIDINE DERIVATIVES AS HSP90 INHIBITOR AND HER2 INHIBITOR | 2009 |
|
RU2532375C2 |
| COMPOUNDS FOR TREATING COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2703995C2 |
| AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | 2008 |
|
RU2481334C2 |
| ANTITUMOR EFFECT STRENGTHENING AGENT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | 2018 |
|
RU2799006C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788174C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
